These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10461822)

  • 1. Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder.
    Fitzgerald KD; Stewart CM; Tawile V; Rosenberg DR
    J Child Adolesc Psychopharmacol; 1999; 9(2):115-23. PubMed ID: 10461822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases.
    Sun TF; Lin PY; Wu CK
    Chang Gung Med J; 2001 Sep; 24(9):587-92. PubMed ID: 11725630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
    Saxena S; Wang D; Bystritsky A; Baxter LR
    J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study.
    Pfanner C; Marazziti D; Dell'Osso L; Presta S; Gemignani A; Milanfranchi A; Cassano GB
    Int Clin Psychopharmacol; 2000 Sep; 15(5):297-301. PubMed ID: 10993132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin reuptake inhibitor-cognitive behavioural therapy-second generation antipsychotic combination for severe treatment-resistant obsessive-compulsive disorder. A prospective observational study.
    Tundo A; Salvati L; Cieri L; Balestrini V; Di Spigno D; Orazi F; Iommi M; Necci R
    Int J Psychiatry Clin Pract; 2022 Nov; 26(4):395-400. PubMed ID: 35323098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.
    Selvi Y; Atli A; Aydin A; Besiroglu L; Ozdemir P; Ozdemir O
    Hum Psychopharmacol; 2011 Jan; 26(1):51-7. PubMed ID: 21308781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.
    McLean CP; Zandberg LJ; Van Meter PE; Carpenter JK; Simpson HB; Foa EB
    J Clin Psychiatry; 2015 Dec; 76(12):1653-7. PubMed ID: 26613263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders.
    Stein DJ; Bouwer C; Hawkridge S; Emsley RA
    J Clin Psychiatry; 1997 Mar; 58(3):119-22. PubMed ID: 9108814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India.
    Hegde A; Kalyani BG; Arumugham SS; Narayanaswamy JC; Math SB; Reddy YC
    J Clin Psychopharmacol; 2016 Aug; 36(4):381-4. PubMed ID: 27219093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.
    Dold M; Aigner M; Lanzenberger R; Kasper S
    Int J Neuropsychopharmacol; 2013 Apr; 16(3):557-74. PubMed ID: 22932229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Hollander E; Baldini Rossi N; Sood E; Pallanti S
    Int J Neuropsychopharmacol; 2003 Dec; 6(4):397-401. PubMed ID: 14604454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
    Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR
    J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study.
    Masi G; Pfanner C; Brovedani P
    J Psychiatr Res; 2013 Aug; 47(8):1007-12. PubMed ID: 23664673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of social phobia with obsessive-compulsive symptoms improved by paroxetine in combination with risperidone.
    Yamauchi K; Ohta K; Taniguchi T; Ohmori T
    Gen Hosp Psychiatry; 2004; 26(3):242-3. PubMed ID: 15121355
    [No Abstract]   [Full Text] [Related]  

  • 18. Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia.
    Dwivedi S; Pavuluri M; Heidenreich J; Wright T
    J Child Adolesc Psychopharmacol; 2002; 12(1):69-70. PubMed ID: 12014598
    [No Abstract]   [Full Text] [Related]  

  • 19. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
    Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
    J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.